Saint Mary’s junior Maddie Helman isn’t celebrating her 21st birthday like most young women. Helman will be running the Walt Disney World Marathon on Jan. 12 to raise money for Girls on the Run, a non-profit organization that provides guidance through running to young girls ages third through fifth grade. In addition to the marathon falling on her 21st birthday, Helman said this year’s marathon marks the 20th anniversary of her mom’s first marathon at Disney. Jamie Helman said she ran her first marathon at Disney two days before her daughter’s first birthday. As a baby, Maddie Helman was hospitalized at Riley Children’s Hospital in Indianapolis three weeks before the marathon, and Jamie Helman said she shifted her focus from training to her daughter. Fortunately, Jamie Helman said her daughter recovered fully before the race. “It was a great accomplishment for us both, and I know running this marathon together on her 21st birthday, in 2014, will be an even greater cause for celebration,” Jamie Helman said. Maddie and Jamie Helman have partnered with the Michiana Council of Girls on the Run through a program called SoleMates, which teaches health and nutrition to the girls and trains them for a 5K race over the course of 12 weeks. according to the Girls on the Run website. SoleMates raises money by encouraging runners to get sponsors, according to the Girls on the Run website. Maddie Helman said her goal is to raise $2,100 in honor of her 21st birthday, and Jamie Helman said her goal is to raise $2,000 in honor of the 20th anniversary of first running the Disney marathon. Maddie and Jamie Helman’s impact on the organization goes beyond just fundraising. Jamie Helman said she serves as the co-chair for development for Girls on the Run, and Maddie Helman said she is a coach. As a coach, Maddie Helman said she understands the direct impact her fundraising will have on the girls. When her team finished the 5K last spring, she knew what she was doing something meaningful, she said. “You could see the sense of accomplishment on their faces,” she said. Maddie Helman said running is a prominent part of her life and her inspiration comes from her favorite running partner: her mom. “My mom inspires me to dig deep and keep going even when it’s not fun,” Maddie Helman said. Maddie Helman said she started running in seventh grade and didn’t enjoy it at all, but she grew to love it and ran her first half marathon in eighth grade. “It’s about mind over matter; it’s about never giving up,” she said. Maddie Helman said her love for running has only grown since, culminating in running her first marathon in Chicago in 2011. “I can’t go for a run and not say thank you,” she said. “It automatically makes the day better.” For more information on Maddie Helman’s training and fundraising, visit her blog at http://twentyseventhmile.wordpress.com/.
May 27, 2009 (CIDRAP News) – Sanofi Pasteur announced today that it has received a novel H1N1 influenza vaccine virus from the Centers for Disease Control and Prevention (CDC), moving the company a step closer to starting production of a vaccine.CDC spokesman Tom Skinner said this afternoon that the agency is also sending the vaccine virus to other manufacturers, located overseas, who should receive the samples within a few days.Jeff McLaughlin, a spokesman for vaccine maker GlaxoSmithKline (GSK), said today he couldn’t confirm GSK’s receipt of the vaccine strain, but added, “We understand that the CDC is in the process of shipping the strain to all the relevant manufacturers.”CDC and World Health Organization (WHO) officials had predicted that the CDC would release H1N1 vaccine viruses to manufacturers by the end of May. WHO officials have said that production of H1N1 vaccines is most likely to begin in July.The preparation of a vaccine strain involves combining a clinical sample of the target virus with another influenza virus that grows in eggs. This process creates a new virus that has some of the properties of the target virus and the ability to grow in eggs, the US Department of Health and Human Services noted today in a fact sheet on vaccine development activities. Most flu vaccines are still produced by growing them in eggs.Wayne Pisano, president of Sanofi Pasteur, said in a news release, “As a company committed to protecting human health, Sanofi Pasteur looks forward to quickly understanding how this virus performs in a vaccine manufacturing environment and developing a working seed that will enable large-scale production.”Sanofi will now begin “passaging” the virus, referring to “the process for acclimating virus to grow in a production environment at optimum yield,” the company said. The process will take about 2 weeks.”Following quality controls, Sanofi Pasteur will be prepared to begin industrial production as soon as directed by public health agencies,” the statement added.Health officials have estimated it would take manufacturers 4 to 6 months from when they receive the vaccine strain to start producing a vaccine in quantity. But a Sanofi spokeswoman said last week that the company may be able to start producing its first doses in 3 to 4 months.Sanofi and GSK both announced within the past few days that they had received US government orders for novel H1N1 vaccines.In related news, the WHO has recommended that vaccines for the novel H1N1 influenza virus be based on an isolate from California, saying most H1N1 viruses isolated so far are very similar to it.A majority of the novel H1N1 viruses isolated so far are antigenically and genetically related to the isolate known as A/California/7/2009 (H1N1), the WHO said in a statement posted online yesterday.The WHO said that its collaborating laboratories, certain regulatory agency laboratories, and other partners are developing reassortant viruses antigenically similar to the California strain for use in vaccines.Skinner, of the CDC, said the agency used the California strain in making the vaccine virus now being released to manufacturers.WHO spokesman Gregory Hartl said several other WHO collaborating centers and regulatory laboratories are developing novel H1N1 vaccine viruses. He said they include St. Jude Children’s Research Hospital in Memphis, a US Food and Drug Administration lab, and facilities in Japan, the United Kingdom, and Australia.See also: May 27 Sanofi press releaseMay 26 CIDRAP News story “Companies receive HHS orders for novel flu vaccine”WHO recommendation on strain for vaccine development